Status:
COMPLETED
Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Asthma in Children
Eligibility:
All Genders
12-18 years
Phase:
PHASE4
Brief Summary
Exercise induced asthma (EIA) is common in adolescents. (Fluticasone furoate (FF)/Vilanterol (VI)) is a once daily inhaler with bronchodilator effect lasting 24 hours. Our objective was to investigate...
Detailed Description
Exercise induced asthma (EIA) is common in adolescents. Relvar® (Fluticasone furoate (FF)/Vilanterol (VI)) is a once daily inhaler with bronchodilator effect lasting 24 hours. Our objective was to inv...
Eligibility Criteria
Inclusion
- Adolescent asthmatics aged 12-18 years
- Symptoms of shortness of breath on exercise and asthmatics before entry to military service
- Referral for evaluation of exercise challenge test
Exclusion
- Baseline FEV1\<65% before exercise test
- Acute illness
- History of intolerance to beta agonists
- Use of the following medications prior to the study was restricted: inhaled corticosteroids or Montelukast (2 weeks), systemic steroids (2 months) and bronchodilators (24 hours)
Key Trial Info
Start Date :
December 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2020
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04750603
Start Date
December 1 2018
End Date
April 15 2020
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Medical Center
Haifa, Israel